disease progression

A recent study published in the journal PLOS ONE described a new technique with the potential to spot brain changes in multiple sclerosis (MS) before the onset of symptoms. The technique, which measures brain dynamic activity and brain entropy, may lead to the development of diagnostic — and possibly prognostic —…

Researchers found that a group of untreated patients with multiple sclerosis (MS) and patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) carry a specific group of hyperactivated immune cells, the inflammatory CD8+ T cells, suggesting a potential common mechanism contributing to disease pathogenesis. The study, “A Preliminary Comparative…

A research team recently showed that key enzymes of energy metabolism pathways are differentially expressed in active and inactive multiple sclerosis (MS) lesions, and may contribute to axonal degeneration in MS. The study, titled “Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions,” was published in the…

Researchers in the United Kingdom recently discovered that a small molecule triggers the destruction of axons, a phenomenon observed in neurodegenerative diseases like multiple sclerosis (MS). The study is titled “Wallerian Degeneration Is Executed by an NMN-SARM1-Dependent Late Ca2+ Influx but Only Modestly Influenced by Mitochondria” and appears in the journal…

Dr. Jerry S. Wolinsky of the University of Texas in Houston, will give the first Kenneth P. Johnson Memorial Lecture at the opening day of the Americas Committee for the Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016 in New Orleans, focusing on distinctions between relapsing and progressive disease forms. ACTRIMS…

The Fifth Tykeson Fellows Conference brought senior multiple sclerosis (MS) scientists together with nearly 100 young research and clinical fellows from the National Multiple Sclerosis Society, MS Society of Canada, and MS International Federation to promote collaboration, networking, and the sharing of research data with the goal of improving patients’ lives and developing…

In a recent study, researchers show how a natural antioxidant within pomegranate seeds is capable of inhibiting demyelination in a mouse model for multiple sclerosis (MS), supporting novel formulations of natural antioxidants as therapeutics for demyelinating diseases. The study, “Treatment of a multiple sclerosis animal model by a novel nano drop formulation of…

In a new study entitled “Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation,” a team of scientists discovered the mechanism by which autoreactive T cells are capable of penetrating a patient’s brain and induce multiple sclerosis. The study was recently published in the advance online issue…

Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D level–related factors,” appeared October 7, 2015 in the journal Neurology.

A new study entitled “Effect of Smoking Cessation on Multiple Sclerosis Prognosis” recently revealed that smoking by patients with multiple sclerosis (MS) post diagnosis accelerates their disease progression course. The study was published in the journal JAMA Neurology and was led by researchers at the…

A new study published in the journal Statistical Methods in Medical Research revealed a new method to determine the disease course in multiple sclerosis (MS) patients. The study is entitled “Joint assessment of dependent discrete disease state processes” and was conducted by researchers at…

Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase 3 clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy). With the successful completion of the futility analysis, AB Science is…

Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, a fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “lesions” result, which appear in the brain and…

A study recently published in the journal PLoS One revealed an excess mortality rate among French patients with multiple sclerosis (MS) that experience the disease for more than 20 years. The study was conducted by researchers at several institutes and hospitals in France, and is entitled “…

The ability to assess risk may decline as multiple sclerosis disease status progresses over time, as determined by a recent study from University of Alberta in Canada. Principal investigator Esther Fujiwara, PhD, and lead author of the study, Ashley Radomski, used the game of dice task (GDT) to challenge patients…

Recent attention to the role of mitochondria in the etiology of multiple sclerosis (what causes the disease) suggests that mitochondrial defects and mitochondrial structural and functional changes may contribute to the disease. Researchers studying mitochondria in multiple sclerosis believe abnormalities in mitochondrial dynamics impact cellular pathways such as inflammation and…

MedDay, a biotechnology company dedicated to developing therapies for nervous system disorders, recently announced encouraging data on its pivotal Phase III clinical trial (MS-SPI) assessing the safety and efficacy of the company’s investigational therapy MD1003 for the treatment of progressive multiple sclerosis (MS). The data was presented at The…

In a recent study published in the journal Nature Communications, LMU clinicians have clarified the lifespan of antibody-producing cells and have also identified a novel biomarker that could be used to monitor autoimmune conditions such as multiple sclerosis and lupus erythematous. The humoral immune response is mediated by cells…

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

Researchers at the Don C. Gnocchi Foundation and the University of Milano in Italy recently discovered that the levels of a specific RNA molecule vary in patients with multiple sclerosis (MS) according to their disease stage and clinical progression. The study was published in the…

Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis…

A new study recently published in the journal Annals of Neurology revealed a potential new therapeutic strategy to halt multiple sclerosis (MS) disease progression. The study is entitled “Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation” and was led by…

Amarantus BioScience has released preliminary data from a blood test for multiple sclerosis (MS) called the MSPrecise diagnostic. The company believes that the test could lead to more accurate diagnoses of MS early in the disease’s progression. MSPrecise is a DNA sequencing test designed to identify specific DNA mutations that are associated with the…

In a recent study entitled “Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy,” researchers unraveled a key role for the cytokine GM-CSF in multiple sclerosis progression, suggesting GM-CSF as a target of IFN-β therapy. The study was published in…

A team led by researchers at the New York University (NYU) Langone Medical Center recently assessed what happens when clinically stable patients with multiple sclerosis (MS) stop taking their medication and found that almost 40% of them experience to some extent a return in disease activity and related symptoms. The…

A team led by researchers at the University of British Columbia in Canada recently published results in the European Journal of Neurology showing that treatment with beta-interferon has no effect on secondary progressive multiple sclerosis (MS) disease onset. The study is entitled “Beta-interferon exposure and…

The National Multiple Sclerosis Society has announced it will grant $28 million to 84 new research projects and training awards focused on multiple sclerosis (MS). The new financial support is included in the society’s comprehensive research strategy, which was designed to not only end MS, but also restore patients’…

MedDay, a Paris, France based biotechnology company specializing in treatment of neurological disorders, has released more information regarding the design of its (MS-SPI) clinical trial that is investigating the efficacy and safety of the investigational medicine MD1003 in treatment of primary and secondary progressive multiple sclerosis (MS). Progressive…

A recent study published in PLOS ONE provides new insights into the relationship between the immune system and neurodegeneration and clinical disability in multiple sclerosis (MS). A team of researchers led by Dr. Shahin Aeinehband from the Neuroimmunology Unit at the Karolinska Institutet in Sweden looked at the association between…

Scientists are developing new tools to understand multiple sclerosis pathogenesis and monitor the benefits of treatments. One of these tools is diffusion tensor imaging (DTI), a novel technique that describes the microstructural organization of white matter tracts in the brain. Although DTI has greater pathological specificity than magnetic resonance imaging…